Geriatric respiratory medicine 2026: from artificial intelligence to personalised management of the multimorbid patient. (PubMed, Eur Respir Rev) - Oct 23, 2026 - "The advent of biological therapies, particularly the use of dupilumab and mepolizumab in eosinophilic COPD, offers a transformative "steroid-sparing" effect, aiming for clinical stability and preserved independence. Finally, the integration of artificial intelligence as "augmented intelligence" and the "4Ms" multidisciplinary model (mentation, medication, mobility, morbidities) provide the necessary tools to navigate clinical complexity. This holistic strategy ensures that technological innovation remains anchored in patient-centred goals."
Journal • Review • CNS Disorders • Immunology • Infectious Disease • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Sarcopenia
|
|
Alessandra Tomasello; Alessandro Vatrella; Andrea Cortegiani; Andrea Maresca; Anna Zito; Antonino Tuttolomondo; Beatrice Ragnoli; Claudio Costantino; Claudio Sorino; Corrado Pelaia; Danilo Di Bona; Giorgio Walter Canonica; Giovanna Elisiana Carpagnano; Luigi Tramonte; Mario Malerba; Nicola Scichilone; Paola Rogliani; Paolo Cameli; Patrizio Vitulo; Simone Scarlata; Stefania Principe
|